HLS Therapeutics (TSE:HLS) Shares Up 0.5% – Should You Buy?

HLS Therapeutics Inc. (TSE:HLS) shares traded up 0.5% on Thursday. The company traded as high as C$4.15 and last traded at C$4.15. Approximately 7,100 shares were traded during mid-day trading, a decline of 80% from the average session volume of 35,203 shares. The stock had previously closed at C$4.13.

Wall Street Analyst Weigh In

HLS has been the topic of several research reports. Canaccord Genuity Group raised shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 13th. Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from C$7.00 to C$8.00 in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to MarketBeat, HLS Therapeutics currently has an average rating of “Strong Buy” and an average target price of C$8.00.

HLS Therapeutics Stock Performance

The company has a debt-to-equity ratio of 75.86, a quick ratio of 1.01 and a current ratio of 1.05. The company has a market cap of C$128.38 million, a price-to-earnings ratio of -15.37 and a beta of -0.50. The company has a fifty day moving average of C$3.94 and a two-hundred day moving average of C$4.23.

HLS Therapeutics (TSE:HLS) last issued its earnings results on Wednesday, August 12th. The company reported C($0.03) earnings per share (EPS) for the quarter. The firm had revenue of C$14.67 million during the quarter. HLS Therapeutics had a negative return on equity of 14.39% and a negative net margin of 15.26%. During the same period in the previous year, the firm posted ($0.09) earnings per share. Equities research analysts anticipate that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.